This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,008,977.00 to the Regents of the University of California, San Francisco to conduct research on the developmental topology of the human cerebral cortex. The key objectives are to understand human brain development and the origins of neurodevelopmental diseases by studying...
This $195,896 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to define the circuit connectivity between glioblastoma, a fatal brain cancer, and diverse neuronal populations in the mouse brain. The research aims to elucidate the role of cholinergic neuromodulatory inputs in regulating glioma progression, with the goal of...
The federal Project Grant award R21NS142585 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $460,940 award, effective June 1, 2025 through May 31, 2027, supports research by The University of Texas MD Anderson Cancer Center to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The goal is to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $717,802 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. The grant supports research aimed at elucidating the cellular and molecular mechanisms underlying the development of a subtype of high-grade glioma brain tumors known as HGG-G34. Specifically, the research project seeks to unravel the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the developmental transition of neural stem cell niches in the human brain. The $1,180,687 award, effective August 1, 2025 through July 31, 2033, will be provided to The Regents of the University of California, San Francisco (UCSF) to characterize the...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,217,078 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to record neural activity in the intact human brain to better understand tumor infiltration. The project will utilize cutting-edge high-resolution microelectrodes, including 1,000-channel thin-film...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $687,279 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on dissecting the orchestrated immune responses to glioblastoma within the native tissue microenvironment. The goal is to improve treatment outcomes by advancing the understanding of the diversity,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to investigate the mechanisms by which the subventricular zone (SVZ) neurogenic niche influences the malignancy of glioblastoma (GBM) brain tumors. The project aims to leverage novel cell-specific proteomic...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $1,341,874.00 to The Regents of the University of California, San Francisco (UCSF) to support research on dendrite development, function, degeneration, and regeneration. The key focus areas of the research include: (1) elucidating the mechanisms that control dendrite development,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...